University of Miami is in the midst of an academic and scientific renaissance. At the root of this sweeping transformation is an infusion of new scientific talent with substantial external funding, a rich track record of collaborative team science, and the firsthand knowledge of how to build innovative research programs. The Miami Clinical Translational Science institute (CTSI) will connect clinical and translational science with service, community and training; foster team science; attract a new generation of clinliDian scientists to human research; and manage the resources needed to sustain success in these areas. With the ultimate goal of improving health, we will catalyze investigators to better understand and mitigate the factors that affect susceptibility, progression, and adverse consequence of disease. Interdisciplinary research will be built on solid bidirectional collaboration with our diverse communities. We will integrate and centralize existing core services across campuses into highly functional Federations with standardized operating procedures and unified governance that are bonded by a common bioinformatics platform. We will emphasize translational research of culturalized medicine, a term we coined to describe culturally targeted, sensitive and appropriate health care. This approach is critical in our own unique community; results will also serve as a general resource to the national CTSA network. We will add functionality to our CITI program, which remains the national standard for research ethics and the protection of human subjects. We have designed the modern form-meets-function Research Commons, the physical home ofthe CTSI. Collaboration is readily evident across CTSI components, including partnerships among UM Schools, Jackson Health System, Miami VA and the University of Puerto Rico. We acknowledge that all of the CTSI components are merely means to a far greater end. Ultimately, the measure of effect of the CTSI will be its ability to improve the health of our patients, their families, and communities.

Public Health Relevance

The University of Miami (UM) will bring together under the single umbrella of the Miami Clinical Translational Science Institute (CTSI) the resources, talent and scientific expertise found in our numerous internationally recognized Schools, Institutes and Centers. The CTSI will enable UM to best serve the health care needs of Its diverse community while growing the size and quality of our translational research workforce and speeding the delivery of scientific discoveries to our patients.

Agency
National Institute of Health (NIH)
Institute
National Center for Advancing Translational Sciences (NCATS)
Type
Mentored Career Development Award (KL2)
Project #
5KL2TR000461-04
Application #
8867316
Study Section
Special Emphasis Panel (ZRR1-CR-1 (01))
Program Officer
Talbot, Bernard
Project Start
2012-06-27
Project End
2017-05-31
Budget Start
2015-06-01
Budget End
2016-05-31
Support Year
4
Fiscal Year
2015
Total Cost
$582,708
Indirect Cost
$43,164
Name
University of Miami School of Medicine
Department
Public Health & Prev Medicine
Type
Schools of Medicine
DUNS #
052780918
City
Coral Gables
State
FL
Country
United States
Zip Code
33146
DeBose-Scarlett, Alexandra; Balise, Raymond; Kwon, Deukwoo et al. (2018) Obstacles to successful treatment of hepatitis C in uninsured patients from a minority population. J Transl Med 16:178
Ramos, Alberto R; Weng, Jia; Wallace, Douglas M et al. (2018) Sleep Patterns and Hypertension Using Actigraphy in the Hispanic Community Health Study/Study of Latinos. Chest 153:87-93
Chen, Han; Cade, Brian E; Gleason, Kevin J et al. (2018) Multiethnic Meta-Analysis Identifies RAI1 as a Possible Obstructive Sleep Apnea-related Quantitative Trait Locus in Men. Am J Respir Cell Mol Biol 58:391-401
Swords, Ronan T; Azzam, Diana; Al-Ali, Hassan et al. (2018) Ex-vivo sensitivity profiling to guide clinical decision making in acute myeloid leukemia: A pilot study. Leuk Res 64:34-41
Vendrame, Francesco; Padilla, Nathalia; Peixoto, Eduardo et al. (2018) Chronic Liraglutide Administration Fails to Suppress Postprandial Glucagon Levels in Type 1 Diabetic Islet Allograft Recipients With Graft Dysfunction. Transplantation 102:e39-e40
Swords, Ronan T; Coutre, Steven; Maris, Michael B et al. (2018) Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, combined with azacitidine in patients with AML. Blood 131:1415-1424
Petrov, Megan E; Weng, Jia; Reid, Kathryn J et al. (2018) Commuting and Sleep: Results From the Hispanic Community Health Study/Study of Latinos SueƱo Ancillary Study. Am J Prev Med 54:e49-e57
Zheng, Shuhua; Leclerc, Gilles M; Li, Bin et al. (2018) Inhibition of the NEDD8 conjugation pathway induces calcium-dependent compensatory activation of the pro-survival MEK/ERK pathway in acute lymphoblastic leukemia. Oncotarget 9:5529-5544
Watts, Justin M; Perez, Aymee; Pereira, Lutecia et al. (2017) A Case of AML Characterized by a Novel t(4;15)(q31;q22) Translocation That Confers a Growth-Stimulatory Response to Retinoid-Based Therapy. Int J Mol Sci 18:
Swords, R T; Watts, J; Erba, H P et al. (2017) Expanded safety analysis of pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukemia and myelodysplastic syndromes. Blood Cancer J 7:e520

Showing the most recent 10 out of 80 publications